{"url_path":"/sec/sxtpw/8-k/2026-06-03/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1946563/0001213900-26-064796-index.html","accession_number":"0001213900-26-064796","cik":"0001946563","ticker":"SXTP","issuer_name":"60 DEGREES PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1946563/0001213900-26-064796-index.html","primary_entity_key":"0001946563","primary_entity_name":"60 DEGREES PHARMACEUTICALS, INC."},"word_count":283,"has_tables":true,"body_markdown":"**Item\n8.01 Other Events**\n\n** **\n\nThe\nCompany intends to submit an application for a Commissioner’s National Priority Review Voucher if the outcome of any interim and/or\nfinal analysis of the Company’s randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis\nsupports moving forward with a New Drug Application submission to the U.S. Food and Drug Administration (“FDA”) before the\nend of the first quarter of 2028. The Company is providing this disclosure to inform investors regarding its current development and\nregulatory plans. The Company’s expectations regarding the trial, any future NDA submission, and any potential voucher application\nare forward-looking statements and are subject to risks and uncertainties, including the outcome of clinical development, interactions\nwith regulatory authorities, and other factors that could cause actual results to differ materially from those anticipated.\n\n \n\n**Cautionary\nStatement Regarding Forward-Looking Statements**\n\n \n\nThis\nCurrent Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of\n1995. Such statements involve risks and uncertainties that could cause the Company’s actual results and financial position\nto differ materially. These risks and uncertainties include uncertainties associated with market conditions and other risks described\nunder the heading “Risk Factors” in the Company’s SEC Filings on Form 10-K and Form 10-Q. The Company assumes no responsibility\nto update or revise any forward-looking statements to reflect events, trends or circumstances after the date hereof.\n\n \n\n1\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**60\nDEGREES PHARMACEUTICALS, INC.**\n\n \n \n\nDate:\nJune 3, 2026\nBy:\n*/s/\nGeoffrey Dow*\n\n \nName: \nGeoffrey\nDow  \n\n \nTitle:\nChief\nExecutive Officer and President\n\n \n\n2"}